Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 18/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.52 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15100943 | 0.90 | MGLL (0.62) | MGLLPLA2G7ABHD6 | |
| SCHEMBL20408684 | 0.85 | MGLL (0.59) | MGLLPLA2G7ABHD6KDM4E | |
| SCHEMBL19628027 | 0.83 | MGLL (0.51) | MGLLPLA2G7ABHD6 | |
| SCHEMBL15101014 | 0.82 | MGLL (0.61) | MGLLPLA2G7ABHD6 | |
| SCHEMBL18074105 | 0.81 | MGLL (0.62) | MGLLPLA2G7ABHD6 | |
| SCHEMBL15094316 | 0.81 | MGLL (0.61) | MGLLPLA2G7ABHD6 | |
| SCHEMBL15101009 | 0.80 | MGLL (0.63) | MGLLPLA2G7ABHD6 | |
| SCHEMBL16744452 | 0.80 | MGLL (0.60) | MGLLPLA2G7ABHD6ALDH1A1 | |
| SCHEMBL21802522 | 0.80 | BACE1 (0.54) | ALDH1A1KDM4EPOLB | |
| SCHEMBL15094855 | 0.79 | MGLL (0.64) | MGLLPLA2G7ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| WO-2020154683-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | MGLL 1/4885PLA2G7 141/4885ABHD6 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.